The UK Health Security Agency (UKHSA) is conducting a human biomonitoring study to improve understanding of levels of PFAS and other chemicals, such as lead, arsenic and flame retardants, in the UK population and any potential implications for health, the agency said in a news story published on 3 November 2026.

The study will analyse blood and urine samples collected through the existing Health Survey England, also covering bisphenols and phthalates. UKHSA said the work will help establish typical background levels of PFAS exposure in the UK and contribute to the wider evidence base, with initial findings from its biomonitoring programme expected in 2027.

Dr Edward Wynne-Evans, Director of Radiation, Chemicals, Climate and Environmental Hazards at UKHSA, said evidence gaps remain around what different exposure levels mean for long-term health, while available evidence suggests any health effects are likely limited. UKHSA said it is not currently recommending routine blood testing for PFAS, noting there is no established clinical intervention linked to a particular PFAS blood level. The independent Committee on Toxicity is carrying out a separate review of evidence on PFAS and health effects.